AI
Friday, June 22, 2007 1:12:15 PM
> Gabapentin ER might be able to find a sweet spot in between Lyrica and the generic. <
Dew, I think that is what they will hit on. If they are only off by a small number of pain-free days relative to Lyrica then they will be able to siphon good market share. It seems many specialty pharmas can make it big with delayed release formulations.
Still waiting for cheaper biologics via transgenic milk to help me retire
HS
Dew, I think that is what they will hit on. If they are only off by a small number of pain-free days relative to Lyrica then they will be able to siphon good market share. It seems many specialty pharmas can make it big with delayed release formulations.
Still waiting for cheaper biologics via transgenic milk to help me retire
HS
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
